Tag: BTK inhibitor for MCL

Home / BTK inhibitor for MCL

Categories

Acalabrutinib with bendamustine and rituximab is approved by the USFDA for previously untreated mantle cell lymphoma

On January 16, 2025, the Food and Drug Administration granted conventional approval to acalabrutinib (Calquence, AstraZeneca) in combination with bendamustine and rituximab for adults with previously ...
btk-inhibitor-for-mcl

Scan the code